A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002

Key facts

Sponsor

Allakos Inc.

Principal Investigator

Marcus Maurer, MD

Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin

Intervention

AK002(drug)

Enrollment

25 enrolled

Eligibility

18-65 years · All sexes

Timeline

2016 – 2018

Study locations (1)

• Charité - Universitätsmedizin Berlin, Berlin, Germany

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Indolent systemic mastocytosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07255638
  A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
  Blueprint Medicines Corporation
• ACTIVE NOT RECRUITINGPHASE2NCT05186753
  (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
  Cogent Biosciences, Inc.
• RECRUITINGPHASE2, PHASE3NCT04910685
  (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
  Blueprint Medicines Corporation
• RECRUITINGPHASE2NCT04655118
  Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
  Telios Pharma, Inc.
• ACTIVE NOT RECRUITINGPHASE2NCT03731260
  (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
  Blueprint Medicines Corporation

See all trials for Indolent systemic mastocytosis →